1. The FDA declined approving Novartis’ biosimilar copy of Amgen’s Neulasta. A Novartis executive said the agency issued a complete response letter in June without giving further details. The drug is used to fight infections in cancer patients. (Reuters)

2. GlaxoSmithKline is using Apple’s ResearchKit for an arthritis study that will record the mobility of 300 clinical trial participants. GSK is Apple’s first pharma partner to use the iOS app. (International Business Times)

3. U.S. and European regulators agreed to review Bristol-Myers Squibb’s Opdivo for metastatic squamous cell carcinoma of the head and neck. The FDA confirmed priority review of the application, which is expected to be reviewed by November 11. (Pharma Times)

4. Drugmakers are testing new ways to get more participants in clinical trials. Companies such as Axovant Sciences and Eli Lilly are monitoring online forums and partnering with car services like Lyft to improve recruitment. (WSJ)

5. GlaxoSmithKline Consumer Healthcare consolidated its global agency roster to nine shops: Grey, Saatchi & Saatchi, Weber Shandwick, Havas, WPP Digital, Edelman, McCann Health, Ogilvy CommonHealth, and Geometry. (Ad Age)